Anti-Ku antibodies: important points to consider

With interest, we read the recent article by Ogawa-Momohara et al.1 which reports the clinical phenotype of patients with anti-Ku autoantibodies and conclude that systemic lupus erythematosus (SLE) and myositis overlap is rare in patients with this antibody reactivity. Ku is a well-known protein heterodimer comprised of 70 and 80 kDa subunits and is best-known for its central role in binding to DNA and the double-strand break DNA repair pathway in mammals.2

There are several challenges when describing the clinical phenotype of patients with anti-Ku antibodies. First, as noted above, Ku is a DNA-binding protein. Consequently, it is difficult but imperative to confirm that patients who test positive for anti-Ku antibodies truly have anti-Ku antibodies, or if the reactivity is caused by antibodies to dsDNA or DNA-binding proteins that are complexed with dsDNA/dsDNA-binding proteins in the serum of patients that then secondarily bind to Ku or dsDNA/dsDNA-binding proteins in an immunoassay (figure 1). In this context, Reeves et al.3 demonstrated that anti-Ku reactivity of certain sera as detected by enzyme linked immunoassay International consensus on antinuclear antibody (ANA) pattern (ELISA) disappeared when the Ku antigen was dissociated from DNA after washing with 0.5 M or higher NaCl buffer, indicating that the reactivity of these sera was via binding of DNA and DNA-binding proteins to Ku. Interaction of various dsDNA-binding proteins complexed with Ku was also reported.4 Thus, an analytically false positive anti-Ku ELISA result can be observed if DNA and other DNA-binding proteins are binding to Ku on the ELISA plate. The same concept applies to other solid phase immunoassays for the detection of anti-Ku antibodies, such as line immunoassays, which are commonly used in clinical laboratory practice.

In addition, if patients are preselected based on HEp-2 indirect immunofluorescence (IIF) patterns, a potential exclusion bias is introduced (figure 2). In the correspondence by Ogawa-Momohara et al.,1 samples were preselected based on the HEp-2 IIF pattern that has been historically associated with anti-Ku antibodies (ICAP nomenclature AC-04; www.anapatterns.org).13 This approach introduces a potential bias because patients with SLE frequently express many autoantibodies and sera accompanied by mixed HEp-2 IIF patterns are very common and presumably were excluded in this study. Therefore, the conclusion that overlap syndrome in anti-Ku-positive patients is rare might not reflect the entire picture. In our experience, anti-Ku antibodies are frequently found in SLE patients potentially associated with overlap features of a myopathy.10 Similarly, anti-Ku antibodies are known as autoantibodies that mark the overlap between myositis and systemic sclerosis.11

The observation that a significant portion of anti-Ku-positive patients also exhibit anti-dsDNA antibodies is complicated by the known variability between anti-dsDNA assays.12 In the correspondence by Ogawa-Momohara et al.,1 no information is

---

**Figure 1** Potential reactivity of anti-dsDNA antibodies in anti-Ku antibody assays. The Ku70/80 heterodimer exhibits dsDNA binding capacities. Consequently, if the antigen used in the Ku assay contains dsDNA, anti-dsDNA antibodies can also bind directly to the Ku70/80-dsDNA complex on the solid phase. In addition, anti-dsDNA/dsDNA complexes that might be present in the sera of patients with autoimmune diseases can generate a positive test result. In addition, other DNA-binding proteins can bind to DNA or the Ku70/80-DNA complex and also serve as autoantigenic targets (not shown for simplicity).
provided on the methods used for the detection of anti-dsDNA and anti-ssDNA antibodies. Therefore, the interpretation of the results in this study is difficult. Unexpectedly, anti-dsDNA reactivity was found predominantly in myositis and not in SLE patients. Noteworthy, recently a novel standard for anti-dsDNA antibodies has been developed and characterised which interestingly also seems to contain anti-Ku reactivity. However, studies are pending to ensure that the new anti-dsDNA standard truly contains antibodies to the Ku70/80 heterodimeric complex and not only high levels of anti-dsDNA antibodies or immune complexes that generate positivity in anti-Ku immunosassays. This may or may not represent a link to the two different clusters of anti-Ku antibodies that have been described and also controversially discussed.

To conclude, we emphasise that defining the clinical phenotype associated with anti-Ku antibodies is challenging and should be based on a systemic study considering all the aforementioned points raised. In particular, selection of serum samples based on a HEp-2 IIF staining pattern does not capture the full spectrum of the clinical associations of this interesting autoantibody.

Michael Mahler, Minoru Satoh, and Marvin J Fritzler

REFERENCES

Correspondence

ICAP – AC-04

No screening

Anti-Ku (monospecific) phenotype

More overlap with other disease

Less overlap with other disease

Anti-Ku phenotype

Figure 2 Potential selection bias based on the HEp-2 indirect immunofluorescence (IIF) pattern. The ICAP AC-04 IIF pattern which can be related to anti-Ku antibodies is characterised by fine tiny speckles throughout the nucleoplasm. The nucleoli may or may not be stained. The chromatin mass of mitotic cells (metaphase, anaphase and telophase) is not stained. According to ICAP, other autoantibodies, such as SS-A/Ro60, SS-B/La, MI-2, TIF1γ and TIF1β, can produce a similar IIF pattern. In addition, autoantibodies, such as anti-dsDNA or anti-chromatin antibodies, can mask or confuse the ICAP AC-4 pattern potentially leading to the selection of mostly monospecific anti-Ku antibodies that might not show overlap features.

Michael Mahler, Minoru Satoh, and Marvin J Fritzler

1 Research, Inova Diagnostics, San Diego, California, USA
2 Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan
3 Medicine, Health Sciences Centre, Calgary, Alberta, Canada

Correspondence to Dr Michael Mahler, Research, INOVA Diagnostics, San Diego, CA 92131-1638, USA; mmahler@inovadx.com

Contributors All the authors contributed to the generation of the manuscript. MM drafted the manuscript, coordinated revisions and generated figures. MS provided insights into the cross-reactivity of interference between anti-Ku and anti-dsDNA antibodies. MIF revised the manuscript and provided details around HEp-2 pattern and potential bias for the definition of the clinical phenotype.

Competing interests MM is an employee of Inova Diagnostics, a company commercialising antibody assays. MIF is a consultant to Inova Diagnostics (San Diego, California, USA) and Werfen International (Barcelona, Spain). No products of Inova Diagnostics are being discussed in the manuscript.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.


Accepted 24 October 2019
Revised 29 October 2019
Accepted 1 November 2019

http://dx.doi.org/10.1136/annrheumdis-2019-216535


ORCID iD
Michael Mahler http://orcid.org/0000-0002-7919-0948

Ann Rheum Dis Month 2019 Vol 0 No 0

Please contact Customer Services on +44 (0)1784 440211 or sales@bmj.com for further information about this license.
Correspondence


